Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Clinical Data and Affymetrix have signed a marketing agreement for a new drug metabolism service using the Affymetrix Drug Metabolizing Enzymes and Transporter Early Access solution.
Subscribe to our email newsletter
Cogenics and Epidauros Biotechnologies, both subsidiaries of Clinical Data, will offer the DMET services on a global basis, with limited exclusivity in Europe. The service will enable pharmaceutical customers to generate comprehensive genetic profiles of a patient’s metabolic status to gain a better understanding of pharmacokinetic drug response.
Affymetrix has been working closely with Cogenics to develop the DMET technology, which directly assays 1,069 total biomarkers in 160 Absorption, Distribution, Metabolism and Excretion (ADME) genes. The kit includes cytochrome p450 enzymes and drug transporters like MDR1, genetic biomarkers with which Cogenics and Epidauros have extensive working experience.
Michael Lutz, global general manager of Cogenics and CEO of Epidauros, said: “The Affymetrix DMET Early Access solution is the only product with comprehensive coverage of all ADME drug metabolism biomarkers to date. We are confident that our Early Access service offering will yield valuable, high-quality data to our pharmaceutical partners on a global basis.”